Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec 27;12(1):e01579.
doi: 10.14309/crj.0000000000001579. eCollection 2025 Jan.

Semaglutide-Associated Gastric Pneumatosis

Andrew M Turunen  1 , Reilly A Coombs  1   2 , Sushil Kumar Garg  2
Affiliations
Case Reports

Semaglutide-Associated Gastric Pneumatosis

Andrew M Turunen et al. ACG Case Rep J. .

Abstract

Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.

Keywords: GLP-1 agonist; gastric pneumatosis; semaglutide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Computed tomography of the abdomen showing gastric pneumatosis in the gastric cardia and proximal fundus.
Figure 2.
Figure 2.
Esophagogastroduodenoscopy findings showing congested, hemorrhagic, and petechial mucosa in the gastric fundus and body.
See this image and copyright information in PMC

References

    1. Ozempic Ozempic.: Dosing, contraindications, side effects, and pill pictures - epocrates online. (n.d.). https://www.epocrates.com/online/drugs/7978/ozempic
    1. Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789. - PMC - PubMed
    1. Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23(2):404–14. - PMC - PubMed
    1. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. - PMC - PubMed
    1. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. - PMC - PubMed

Publication types

LinkOut - more resources